$CLRB

Cellectar Biosciences reported a DLBCL patient achieving a complete response for over eight years after a single dose of iopofosine I 131. The company plans to begin dosing in its Phase 3 WM study in Q1 2027 and aims for an FDA filing in H1 2027, according to the company.

Cellectar Biosciences (CLRB) will report Q3'26 earnings on October 29. Analysts expect 0 USD revenue and a loss of 0.56 USD per share. Details are available on the company's financials page.

Cellectar Biosciences (CLRB) reported positive Phase 2b trial results for iopofosine I 131 in Waldenström macroglobulinemia patients, with 87.5% overall response rate. The company plans a Phase 3 trial and FDA filing in 2027. Shares fell 15.11% on the news.

Cellectar Biosciences (CLRB) reported Q2 earnings, highlighting strong clinical data for iopofosine and a clear regulatory path. The CLOVER-WaM study showed high response rates in Waldenstrom’s macroglobulinemia. The company plans a Phase III trial and accelerated approval submission in 2027. Financing of up to $140M was secured, improving cash position to $34M. R&D expenses increased, widening net loss to $6.9M. Management acknowledged dilution risks and operational challenges.

Cellectar Biosciences (CLRB) reported Q2 2026 earnings with $34M in cash, up from $13.2M at year-end 2025. The company raised $31.7M net from a May 2026 financing, with potential for $140M total. R&D expenses increased to $4.6M, while net loss was $6.9M. Clinical data showed promising results for iopofosine I 131 in Waldenstrom's macroglobulinemia, with a 79.2% response rate in post-BTKi patients. The company plans to initiate a Phase 3 trial by late 2026 or early 2027, targeting mid-2027 NDA su

Cellectar Biosciences (CLRB) reported Q2 2026 results on an earnings call, including $34.0M cash at June 30, 2026, $4.6M R&D expense, and a $6.9M net loss ($0.57/share). Management discussed Phase 3 WM site activation, targeted accelerated-approval submission in March-April 2027, CLR 125 data later in 2026/early 2027, and actinium-225 multi-sourcing. The May financing added $35M upfront plus milestone warrants up to $105M.

Cellectar Biosciences (CLRB) reported Q2 2026 results. Cash and cash equivalents were $34.0M as of June 30, 2026, funding operations into Q2 2027. R&D rose to $4.6M from $2.4M a year earlier; net loss was $6.9M, or $0.57/share. Pipeline progress includes Phase 3 prep for Iopofosine I 131 in Waldenström macroglobulinemia and Phase 1b enrollment for CLR 125 in triple-negative breast cancer.

Cellectar Biosciences (NASDAQ: CLRB) reported Q2 2026 results and corporate updates. It initiated site activation for a Phase 3 confirmatory trial of iopofosine I 131 in Waldenström macroglobulinemia, with an NDA planned for mid-2027 under FDA Accelerated Approval. ASCO data showed 79.2% MRR (n=24) post-BTKi. CLR 125 Phase 1b TNBC enrollment began. Cash was $34.0M at June 30, 2026.

Cellectar Biosciences, Inc. (CLRB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Appro

Cellectar Biosciences (NASDAQ: CLRB) said a Phase 1 open-label study of iopofosine I 131 plus low-dose dexamethasone in 31 relapsed or refractory multiple myeloma patients was published in Cancers. Among 26 efficacy-evaluable patients, 84.6% had stable disease or better, with a 30% overall response rate in those receiving at least 60 mCi. Safety was manageable, mainly reversible cytopenias.